ketanserin has been researched along with Cancer of Head in 1 studies
Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.
ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lawrence, CM | 1 |
| Matthews, JN | 1 |
| Cox, NH | 1 |
1 trial available for ketanserin and Cancer of Head
| Article | Year |
|---|---|
The effect of ketanserin on healing of fresh surgical wounds.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Head and Neck Neoplasms; Humans; Ketans | 1995 |